Joshua A. Kazam, Director at Allogene Therapeutics, Inc. (ALLO), bought 15,000 shares at $12.60 ($189K) on 2022-01-12, disclosed to the SEC on 2022-01-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| CAPR | BUY | 2015-01-22 | $25K | — | Filing → |
| NLTX | BUY | 2009-03-13 | $383 | — | Filing → |
| NLTX | BUY | 2008-12-16 | $4K | — | Filing → |